GRACE :: Lung Cancer
Dr West

Lung Cancer FAQ: What is EGFR, and what are the molecular tests related to it?

Share
download as a pdf file Download PDF of this page

EGFR stands for epidermal growth factor receptor, which is a molecule on the surface of many cancer cells that can be activated to activate signals that promote cell growth and cell division. Though this target may play a role for many kinds of cancer, non-small cell lung cancer (NSCLC) is one type in which this target protein is seen in a majority of people’s cancers. In a minority (about 10% in North America and Europe, but closer to 20-30% in Asian populations) who typically have little or no history of smoking and have an adenocarcinoma subtype of NSCLC, there is a particular mutation that leads to activation of the receptor and the downstream cascade of cellular activity that appears to often do a large part of driving the cancer mechanism. Consequently, drugs that block the EGFR target, specifically oral drugs that inhibit the tyrosine kinase portion on the back end, intracellular (within the cell) portion of the receptor (EGFR tyrosine kinase inhibitors, or TKIs, with examples being Tarceva (erlotinib) and Iressa (gefitinib) can sometimes lead to dramatic and long lasting tumor shrinkage. In a larger proportion of patients with NSCLC, these agents can provide a more modest benefit, consistent with the concept that the EGFR pathway is a contributing pathway for the cancer but not the primary driving force.

Another mechanism of blocking the EGFR pathway is by blocking the extracellular (outside the cell) portion of the receptor with a monoclonal antibody that is administered intravenously. Erbitux (cetuximab) is an antibody against EGFR that has been studied and appears to have a very modest degree of activity in advanced NSCLC, though its benefit has been equivocal enough that it is not FDA approved nor widely used as a treatment for NSCLC at this time.

Several different molecular markers have been developed as potential correlates of the activity of EGFR inhibitors. The three main ones are EGFR mutations, which are specific changes in the DNA sequence of the EGFR gene, EGFR fluorescence in situ hybridization (FISH), which measures the number of copies of the EGFR gene in cancer cells, and EGFR immunohistochemistry (IHC), which measures the amount of the protein itself on the surface of the cancer cells. Though there is some evidence to support that being positive for EGFR IHC, FISH, and an activating mutation are all associated with a greater probability of benefiting from EGFR inhibitors, the evidence has converged on a consistent finding that patients with an EGFR mutation are highly likely to receive a very significant benefit from EGFR TKIs, while the trends are less strong and less consistent for those with a high EGFR gene copy number (or gene amplification) as measured by FISH, and the least clear and consistent results of all for EGFR status by IHC. Over time, EGFR mutation status has appeared as the key predictor of strongest benefit with EGFR TKIs. In contrast, none of these markers is clearly associated with benefit from EGFR monoclonal antibodies like Erbitux, though the study that demonstrated a benefit with Erbitux was restricted to patients who had at least some EGFR protein expression on their tumor cells, as measured by IHC.

Further information is available through these links:

Basics of EGFR biology, with figures

EGFR molecular markers

EGFR mutations demystified

Importance of EGFR mutations on IPASS trial of Asian never-smokers

EGFR TKIs for patients with an EGFR mutation

Erbitux with chemo: FLEX trial in advanced NSCLC

Podcast on molecular markers in lung cancer, with focus on EGFR


3 Responses to Lung Cancer FAQ: What is EGFR, and what are the molecular tests related to it?

  • Laya D. says:

    Thank you for the explanation, Dr. West. Another term that I’ve heard is “EGFR Wildtype.” What is that?

    Laya

  • dfourer says:

    I read this article and six articles referenced at the end, strait through. All together an excellent review. This must seem intimidating to someone new to all this. Still, I really appreciate the background. I don’t like looking at countless trial results and skipping the background science.

    A while back, I read an account of the first successful treatment of childhood leukemia using 4 drugs in combination, way back in 1965. Isn’t this what we hope to do for Lung cancer? I thought it quite worth my time to read about it (The New Yorker, May 17, 2010, page 69).

    David

  • Dr West
    Dr West says:

    EGFR wild type means the normal, non-mutated form of EGFR.

    Thanks for the comments, David, and the good tip on the history of some of oncology’s bigger triumphs to remind us how far we’ve come.

Leave a Reply

Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share
download as a pdf file Download PDF of this page

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share
download as a pdf file Download PDF of this page

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share
download as a pdf file Download PDF of this page

Subscribe to the GRACEcast Podcast on iTunes

Share
download as a pdf file Download PDF of this page

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share
download as a pdf file Download PDF of this page

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243